Accolade Is Maintained at Buy by Guggenheim
Accolade Is Maintained at Buy by Guggenheim
Accolade Price Target Cut to $13.00/Share From $17.00 by Guggenheim
Accolade Price Target Cut to $13.00/Share From $17.00 by Guggenheim
Guggenheim Maintains Buy on Accolade, Lowers Price Target to $13
Guggenheim analyst Sandy Draper maintains Accolade (NASDAQ:ACCD) with a Buy and lowers the price target from $17 to $13.
Express News | Accolade Inc : Guggenheim Cuts Target Price to $13 From $17
Express News | Accolade Inc : Jefferies Cuts Target Price to $9 From $10
Accolade Is Maintained at Equal-Weight by Wells Fargo
Accolade Is Maintained at Equal-Weight by Wells Fargo
Express News | Wells Fargo Maintains Equal-Weight on Accolade, Lowers Price Target to $10
Accolade, Inc. (NASDAQ:ACCD) Q4 2024 Earnings Call Transcript
Accolade, Inc.'s (NASDAQ:ACCD) Latest 14% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Key Insights Significantly high institutional ownership implies Accolade's stock price is sensitive to their trading actions 54% of the business is held by the top 8 shareholders Analyst forecast
Express News | Accolade Inc : Stephens Cuts Target Price to $14 From $16
EDIT, CLNE and NIU Are Among After Hour Movers
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Aon plc (NYSE:AON) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Aon posted adjusted earnings of $5.66 per share, missing ma
Earnings Call Summary | Accolade(ACCD.US) Q4 2024 Earnings Conference
The following is a summary of the Accolade, Inc. (ACCD) Q4 2024 Earnings Call Transcript:Financial Performance:Accolade Inc. reported Q4 revenue of $125 million, a 30% pro forma growth over the same p
Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating
Accolade (ACCD) has an average rating of outperform and price targets ranging from $10 to $18, according to analysts polled by Capital IQ. Price: 7.92, Change: -1.27, Percent Change: -13.82
12 Health Care Stocks Moving In Friday's Intraday Session
GainersBiodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 61.4% to $1.17 during Friday's regular session. The company's market cap stands at $5.1 million. Agenus (NASDAQ:AGEN) shares rose 32.53% to $11.
Accolade Price Target Cut to $16.00/Share From $18.00 by Canaccord Genuity
Accolade Price Target Cut to $16.00/Share From $18.00 by Canaccord Genuity
Accolade Is Maintained at Buy by Needham
Accolade Is Maintained at Buy by Needham
Express News | Needham Maintains Buy on Accolade, Lowers Price Target to $13
Accolade Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/26/2024 50.29% Needham $12 → $13 Maintains Buy 04/22/2024 50.29% Stifel $15 → $13 Maintains Buy 02/26/2
Express News | Accolade Inc : Morgan Stanley Cuts Target Price to $12 From $13